C4 Therapeutics Cabinets BRAF Blocker, Goes All-In on A number of Myeloma Drug

C4 Therapeutics will not pour cash into its investigational BRAF inhibitor CFT1946, within the title of “strategic capital allocation,” the biotech introduced Wednesday.

As an alternative, C4 will focus its efforts and sources on its a number of myeloma drug candidate cemsidomide, whereas searching for improvement companions that may “advance the BRAF program given the excessive unmet want and robust degrader rationale for treating BRAF V600 mutant stable tumors.”

Earlier than being placed on the backburner, CFT1946 had a Section I readout final September, which demonstrated that the drug candidate had an encouraging pharmacokinetic and security profile, based on the corporate.

These early outcomes underscored the potential of CFT1946 to “disrupt the present therapy panorama” in these particular stable tumors, CEO Andrew Hirsch stated on the time. BRAF is a signaling protein that regularly carries a V600 mutation in a number of most cancers sorts.

Information from a Section I dose-escalation research of CFT1946 in sufferers with melanoma or colorectal most cancers shall be offered at an upcoming scientific congress, based on C4’s press announcement on Wednesday.

C4 introduced its determination to place CFT1946 on ice alongside its first-quarter earnings report. Within the first three months of 2025, the biotech recorded a web lack of $26.3 million, a slight enchancment from its $28.4 million deficit throughout the identical interval final 12 months. By the top of Q1, C4 had $234.7 million in money, money equivalents and marketable securities, sufficient to maintain it afloat into 2027.

The Massachusetts-based biotech will now focus its efforts and sources on cemsidomide, an experimental oral degrader of IKZF1/3 transcription components being trialed for a number of myeloma. Based on C4, Section I information for the drug candidate recommend a “compelling” response profile for cemsidomide on this indication, hitting an total response charge of fifty% as of an April 30 information cutoff.

C4 plans to wrap up the Section I dose-escalation trial for cemsidomide and current its information by the third quarter.

Apart from a number of myeloma, C4 can be finding out cemsidomide in non-Hodgkin’s lymphoma, for which it is usually conducting Section I dose-escalation analyses. The biotech is constructing as much as a readout on this indication by year-end. C4 is awaiting sure “regulatory suggestions” concerning cemsidomide’s registrational improvement, which it expects to obtain by mid-year.